Green Alpha Advisors, LLC / CRSP
Green Alpha Advisors, LLC’s Crispr Therapeutics AG Position
Does Green Alpha Advisors, LLC own Crispr Therapeutics AG (CRSP)? Yes — 57.0K shares worth $3M (+2.67% of its 13F portfolio) as of Q1 2026, up from 55.7K shares the prior filed quarter.
Position Value
$3M
Q1 2026
Shares
57.0K
% of Portfolio
+2.67%
Quarters Held
20
currently held
Position History CRSP
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 57.0K | $3M | +2.67% |
| Q4 2025 | 55.7K | $3M | +2.68% |
| Q3 2025 | 55.0K | $4M | +3.44% |
| Q2 2025 | 58.5K | $3M | +2.72% |
| Q1 2025 | 57.4K | $2M | +2.08% |
| Q4 2024 | 24.6K | $969,397 | +0.78% |
| Q3 2024 | 19.2K | $900,043 | +0.71% |
| Q2 2024 | 19.6K | $1M | +0.85% |
| Q1 2024 | 27.0K | $2M | +1.33% |
| Q4 2023 | 24.6K | $2M | +1.11% |
| Q3 2023 | 34.9K | $2M | +1.22% |
| Q2 2023 | 34.4K | $2M | +1.27% |
| Q1 2023 | 32.6K | $1M | +1.03% |
| Q4 2022 | 30.6K | $1M | +1.03% |
| Q3 2022 | 27.5K | $2M | +1.52% |
| Q2 2022 | 228.3K | $14M | +3.19% |
| Q1 2022 | 25.5K | $2M | +1.08% |
| Q4 2021 | 17.2K | $1M | +0.88% |
| Q3 2021 | 14.9K | $2M | +1.15% |
| Q2 2021 | 12.7K | $2M | +1.40% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Green Alpha Advisors, LLC’s full portfolio or all institutional holders of CRSP.